Key facts
- 410 Medical’s last known valuation is $15.1M (Oct 2019).
- It has raised $46.3M across 5 recorded rounds; the latest was Early Stage VC ($25.7M) in Oct 2022.
- Notable investors include Duke Capital Partners, Hatteras Venture Partners, Sovereign's Capital, Catalyst by Wellstar, OSF Ventures — 20 tracked in total.
- 410 Medical has filed 7 Form Ds with the SEC since 2017, most recently Mar 2025 ($25.7M sold to 44 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 5 rounds
- ·The complete investor list — 20 names
- ·Watchlist + deal alerts for 410 Medical
Funding rounds
5 roundsAbout 410 Medical
Developer of a rapid infuser device designed to help critically ill patients requiring volume resuscitation. The company's device enhances the speed and efficiency of fluid resuscitation and improves care for patients with life-threatening illnesses such as sepsis and shock, enabling healthcare providers to easily deliver blood, blood components, crystalloids, or colloid fluids.
- Sector
- Healthcare
- HQ
- Durham, NC, United States
- Founded
- 2013
- Employees
- 38
- Website
- 410medical.com/
- Ownership
- Privately Held (backing)
410 Medical doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in 410 Medical shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on 410 Medical in its N-PORT filings yet. We sweep new filings monthly.